Welcome to LookChem.com Sign In|Join Free

CAS

  • or

503-11-7 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 503-11-7 Structure
  • Basic information

    1. Product Name: epoxypropionic acid
    2. Synonyms: epoxypropionic acid;2,3-EPOXYPROPANOIC ACID;glycidic acid;Epihydrinic acid;Oxirane-2-carboxylic acid;2-Oxiranecarboxylic acid;2,3-Epoxy-propionsaeure;acide 2,3-epoxypropanoique
    3. CAS NO:503-11-7
    4. Molecular Formula: C3H4O3
    5. Molecular Weight: 89.07
    6. EINECS: 207-961-7
    7. Product Categories: Heterocycle-other series
    8. Mol File: 503-11-7.mol
    9. Article Data: 9
  • Chemical Properties

    1. Melting Point: 196 °C (decomp)
    2. Boiling Point: 246.5 °C at 760 mmHg
    3. Flash Point: 122.8 °C
    4. Appearance: /
    5. Density: 1.557g/cm3
    6. Vapor Pressure: 0.00876mmHg at 25°C
    7. Refractive Index: 1.511
    8. Storage Temp.: N/A
    9. Solubility: N/A
    10. PKA: 3.59±0.20(Predicted)
    11. CAS DataBase Reference: epoxypropionic acid(CAS DataBase Reference)
    12. NIST Chemistry Reference: epoxypropionic acid(503-11-7)
    13. EPA Substance Registry System: epoxypropionic acid(503-11-7)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 503-11-7(Hazardous Substances Data)

503-11-7 Usage

Description

Epoxypropionic acid, also known as Oxirane-2-carboxylic acid, is an organic compound characterized by the presence of an epoxide group and a carboxylic acid functional group. It is a versatile building block in the synthesis of various pharmaceuticals and other chemical products due to its unique structural features.

Uses

Used in Pharmaceutical Industry:
Epoxypropionic acid is used as a reactant in the synthesis of glutathione peptidomimetics, which are components of antiparkinson prodrugs. These prodrugs are designed to improve the treatment of Parkinson's disease by enhancing the delivery and efficacy of the active pharmaceutical ingredients.

Check Digit Verification of cas no

The CAS Registry Mumber 503-11-7 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,0 and 3 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 503-11:
(5*5)+(4*0)+(3*3)+(2*1)+(1*1)=37
37 % 10 = 7
So 503-11-7 is a valid CAS Registry Number.
InChI:InChI=1/C3H4O3/c4-3(5)2-1-6-2/h2H,1H2,(H,4,5)

503-11-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name oxirane-2-carboxylic acid

1.2 Other means of identification

Product number -
Other names Oxiranecarboxylic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:503-11-7 SDS

503-11-7Synthetic route

oxiranyl-methanol
556-52-5

oxiranyl-methanol

glycidic acid
503-11-7

glycidic acid

Conditions
ConditionsYield
With sodium periodate; ruthenium trichloride In water; acetonitrile at 20℃; for 2h;47%
With sodium periodate; ruthenium dioxide dihydrate In tetrachloromethane; water; acetonitrile at 20℃; for 2.83333h; Inert atmosphere;Ca. 3.00 g
acrylic acid
79-10-7

acrylic acid

glycidic acid
503-11-7

glycidic acid

Conditions
ConditionsYield
With hypochloric acid Behandeln des Reaktionsprodukts mit alkoh. Kali;
With perchloric acid; acetic acid; quinolinium chlorochromate(VI) at 39.85℃; Kinetics; Further Variations:; Temperatures;
With perchloric acid; dihydrogen peroxide In water; acetonitrile; tert-butyl alcohol at 59.84℃; under 760.051 Torr; for 1h; Inert atmosphere;56 %Chromat.
With perchloric acid; tetraethylammonium chlorochromate(VI); sodium perchlorate; acetic acid In water at 29.84℃; for 24h; Kinetics; Concentration; Temperature;
With 7H2O*3H3N*3H(1+)*[FeMo6O18(OH)6](3-); dihydrogen peroxide; sodium hydrogencarbonate In acetonitrile at 50℃; for 10h; chemoselective reaction;95 %Chromat.
3-chloro-2-hydroxypropanoic acid
1713-85-5

3-chloro-2-hydroxypropanoic acid

glycidic acid
503-11-7

glycidic acid

Conditions
ConditionsYield
With -base Kinetik; dl-glycidic acid;
With potassium hydroxide dl-glycidic acid;
acide 2-bromo-3-hydroxy propanoique
160732-12-7

acide 2-bromo-3-hydroxy propanoique

glycidic acid
503-11-7

glycidic acid

Conditions
ConditionsYield
With potassium hydroxide; nitric acid 1.) methanol, -40 deg C --> 0 deg C; 2.) water, -5 deg C, 1 h; Yield given;
acrolein
107-02-8

acrolein

A

acrylic acid
79-10-7

acrylic acid

B

glycidic acid
503-11-7

glycidic acid

Conditions
ConditionsYield
With Oxone In water-d2 for 0.25h; Product distribution; Ambient temperature; pH 6.8 (phosphate buffer);
oxiranyl-methanol
556-52-5

oxiranyl-methanol

A

Glycidaldehyde
765-34-4

Glycidaldehyde

B

glycidic acid
503-11-7

glycidic acid

Conditions
ConditionsYield
With Acetobacter pasteurianus LMG 1635 In water at 30℃; Kinetics;
sodium salt of/the/ β-chloro-lactic acid

sodium salt of/the/ β-chloro-lactic acid

glycidic acid
503-11-7

glycidic acid

Conditions
ConditionsYield
With sodium ethanolate
3-chloro-2-hydroxypropanoic acid
1713-85-5

3-chloro-2-hydroxypropanoic acid

alcoholic sodium hydroxide

alcoholic sodium hydroxide

glycidic acid
503-11-7

glycidic acid

2-chloro-3-hydroxypropionic acid
138250-73-4, 134267-54-2, 134267-57-5

2-chloro-3-hydroxypropionic acid

alcoholic potash

alcoholic potash

glycidic acid
503-11-7

glycidic acid

D-(+)-camphoric acid
124-83-4

D-(+)-camphoric acid

water
7732-18-5

water

KMnO4

KMnO4

alkali

alkali

A

oxalic acid
144-62-7

oxalic acid

B

glycidic acid
503-11-7

glycidic acid

Conditions
ConditionsYield
at 20℃;
D-(+)-camphoric acid
124-83-4

D-(+)-camphoric acid

water
7732-18-5

water

KMnO4

KMnO4

alkali

alkali

A

formic acid
64-18-6

formic acid

B

oxalic acid
144-62-7

oxalic acid

C

acetic acid
64-19-7

acetic acid

D

glycidic acid
503-11-7

glycidic acid

D-(+)-camphoric acid
124-83-4

D-(+)-camphoric acid

water
7732-18-5

water

KMnO4

KMnO4

alkali

alkali

A

2,3,3-trimethylsuccinic acid
2103-16-4

2,3,3-trimethylsuccinic acid

B

oxalic acid
144-62-7

oxalic acid

C

glycidic acid
503-11-7

glycidic acid

D

butyric acid
107-92-6

butyric acid

D-(+)-camphoric acid
124-83-4

D-(+)-camphoric acid

water
7732-18-5

water

KMnO4

KMnO4

alkali

alkali

A

(+-)-camphoronic acid
508-34-9, 2385-74-2, 102571-53-9

(+-)-camphoronic acid

B

oxalic acid
144-62-7

oxalic acid

C

glycidic acid
503-11-7

glycidic acid

D

camphanoic acid

camphanoic acid

2-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)ethan-1-amine
165749-18-8

2-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)ethan-1-amine

glycidic acid
503-11-7

glycidic acid

N-[O,O'-di-(tert-butyl-dimethylsilyl)dopaminyl]-glycidamide
1047684-30-9

N-[O,O'-di-(tert-butyl-dimethylsilyl)dopaminyl]-glycidamide

Conditions
ConditionsYield
Stage #1: glycidic acid With 4-methyl-morpholine; isobutyl chloroformate In dichloromethane at 0℃; for 1h; Cooling with ice; Inert atmosphere;
Stage #2: 2-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)ethan-1-amine With 4-methyl-morpholine In dichloromethane at 0℃; Inert atmosphere;
56%
1,3-Benzothiazole
95-16-9

1,3-Benzothiazole

glycidic acid
503-11-7

glycidic acid

2-(oxiran-2-yl)benzo[d]thiazole

2-(oxiran-2-yl)benzo[d]thiazole

Conditions
ConditionsYield
With ammonium peroxydisulfate; anthocyanin In dichloromethane; water at 20℃; Minisci Aromatic Substitution; Irradiation; Green chemistry;55%
1-Adamantanamine
768-94-5

1-Adamantanamine

glycidic acid
503-11-7

glycidic acid

N-adamantylglycidamide
1047684-27-4

N-adamantylglycidamide

Conditions
ConditionsYield
Stage #1: glycidic acid With 4-methyl-morpholine; isobutyl chloroformate In dichloromethane at 0℃; for 1h; Cooling with ice; Inert atmosphere;
Stage #2: 1-Adamantanamine With 4-methyl-morpholine In dichloromethane at 0℃; Inert atmosphere;
52%
oxalyl dichloride
79-37-8

oxalyl dichloride

N-{5-[(2-aminoimidazo[1,2-b]pyridazin-6-yl)oxy]-2-methylphenyl}-1,3-dimethyl-1H-pyrazole-5-carboxamide hydrochloride
1005784-98-4

N-{5-[(2-aminoimidazo[1,2-b]pyridazin-6-yl)oxy]-2-methylphenyl}-1,3-dimethyl-1H-pyrazole-5-carboxamide hydrochloride

glycidic acid
503-11-7

glycidic acid

1,3-dimethyl-N-[2-methyl-5-({2-[(oxirane-2-ylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)phenyl]-1H-pyrazole-5-carboxamide
1005785-28-3

1,3-dimethyl-N-[2-methyl-5-({2-[(oxirane-2-ylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)phenyl]-1H-pyrazole-5-carboxamide

Conditions
ConditionsYield
In tetrahydrofuran; N,N-dimethyl acetamide; N,N-dimethyl-formamide52%
tert-butyl (2S,4R)-4-(2,3-dichloro-6-methoxyphenyl)-2-(hydroxymethyl)piperidine-1-carboxylate

tert-butyl (2S,4R)-4-(2,3-dichloro-6-methoxyphenyl)-2-(hydroxymethyl)piperidine-1-carboxylate

glycidic acid
503-11-7

glycidic acid

[(2S,4R)-4-(2,3-dichloro-6-methoxyphenyl)-1-(oxirane-2-carbonyl)piperidin-2-yl]methanol

[(2S,4R)-4-(2,3-dichloro-6-methoxyphenyl)-1-(oxirane-2-carbonyl)piperidin-2-yl]methanol

Conditions
ConditionsYield
With triethylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; for 1h;40%
N-((3R,6S)-6-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine

N-((3R,6S)-6-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine

glycidic acid
503-11-7

glycidic acid

racemic-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl](oxiran-2-yl)methanone

racemic-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl](oxiran-2-yl)methanone

Conditions
ConditionsYield
Stage #1: glycidic acid With oxalyl dichloride; N,N-dimethyl-formamide In dichloromethane at 20℃; for 0.5h; Inert atmosphere;
Stage #2: N-((3R,6S)-6-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine With N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 1h;
23%
trans-N-(4-aminocyclohexyl)-2-(4-chloro-3-fluorophenoxy)acetamide

trans-N-(4-aminocyclohexyl)-2-(4-chloro-3-fluorophenoxy)acetamide

glycidic acid
503-11-7

glycidic acid

trans-N-(4-(2-(4-chloro-3-fluorophenoxy)acetamido)cyclohexyl)oxirane-2-carboxamide

trans-N-(4-(2-(4-chloro-3-fluorophenoxy)acetamido)cyclohexyl)oxirane-2-carboxamide

Conditions
ConditionsYield
Stage #1: trans-N-(4-aminocyclohexyl)-2-(4-chloro-3-fluorophenoxy)acetamide With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In N,N-dimethyl-formamide at 20℃; for 0.5h;
Stage #2: glycidic acid In N,N-dimethyl-formamide at 20℃;
20%
7-chloro-1H-indole
53924-05-3

7-chloro-1H-indole

glycidic acid
503-11-7

glycidic acid

3-(7-chloro-1H-indol-3-yl)-2-hydroxy-propionic acid
870481-95-1

3-(7-chloro-1H-indol-3-yl)-2-hydroxy-propionic acid

Conditions
ConditionsYield
With tin(IV) chloride In tetrachloromethane at 0℃; for 1.5h;7%
4-[7-[6-amino-4-methyl-3-(trifluoromethyl)-2-pyridyl]-6-chloroquinazolin-4-yl]piperazine-2-carbonitrile

4-[7-[6-amino-4-methyl-3-(trifluoromethyl)-2-pyridyl]-6-chloroquinazolin-4-yl]piperazine-2-carbonitrile

glycidic acid
503-11-7

glycidic acid

4-[7-[6-amino-4-methyl-3-(trifluoromethyl)-2-pyridyl]-6-chloroquinazolin-4-yl]-1-(oxirane-2-carbonyl)piperazine-2-carbonitrile

4-[7-[6-amino-4-methyl-3-(trifluoromethyl)-2-pyridyl]-6-chloroquinazolin-4-yl]-1-(oxirane-2-carbonyl)piperazine-2-carbonitrile

Conditions
ConditionsYield
With (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 25℃; for 24h;3.1%
glycidic acid
503-11-7

glycidic acid

2-hydroxy-3-iodo-propionic acid
57101-70-9

2-hydroxy-3-iodo-propionic acid

Conditions
ConditionsYield
With hydrogen iodide
glycidic acid
503-11-7

glycidic acid

(RS)-isoserine
632-12-2

(RS)-isoserine

Conditions
ConditionsYield
With ammonia; water at 120℃; inactive α-oxy-β-amino-propionic acid;
With ethanol; ammonia inactive α-oxy-β-amino-propionic acid;
glycidic acid
503-11-7

glycidic acid

glyceric acid
473-81-4

glyceric acid

Conditions
ConditionsYield
With water
glycidic acid
503-11-7

glycidic acid

(R,S)-3-bromo-2-hydroxypropanoic acid
32777-03-0

(R,S)-3-bromo-2-hydroxypropanoic acid

Conditions
ConditionsYield
With hydrogen bromide
glycidic acid
503-11-7

glycidic acid

2,3,3-trimethylsuccinic acid
2103-16-4

2,3,3-trimethylsuccinic acid

Conditions
ConditionsYield
With hydrogen bromide at 140℃;
With phosphorus halides nachfolgende Behandlung mit Wasser;
at 170 - 220℃; das Anhydrid entsteht;
Conditions
ConditionsYield
With sulfuric acid
With potassium hydroxide
glycidic acid
503-11-7

glycidic acid

3-chloro-2-hydroxypropanoic acid
1713-85-5

3-chloro-2-hydroxypropanoic acid

Conditions
ConditionsYield
With hydrogenchloride
dimethyl amine
124-40-3

dimethyl amine

glycidic acid
503-11-7

glycidic acid

A

3-dimethylamino-2-hydroxy-propionic acid
108724-17-0

3-dimethylamino-2-hydroxy-propionic acid

B

N,N-dimethylserine
2812-35-3

N,N-dimethylserine

Conditions
ConditionsYield
In diethyl ether; water for 2h; Product distribution; Ambient temperature;
methylamine
74-89-5

methylamine

glycidic acid
503-11-7

glycidic acid

A

methyl-cycloserine
2076-49-5

methyl-cycloserine

B

2-hydroxy-3-methylamino-propionic acid

2-hydroxy-3-methylamino-propionic acid

Conditions
ConditionsYield
In diethyl ether; water for 3h; Product distribution; Ambient temperature;
glycidic acid
503-11-7

glycidic acid

A

serin
302-84-1

serin

B

(RS)-isoserine
632-12-2

(RS)-isoserine

Conditions
ConditionsYield
With ammonia In diethyl ether; water for 6h; Product distribution; Ambient temperature;
ammonia
7664-41-7

ammonia

glycidic acid
503-11-7

glycidic acid

(RS)-isoserine
632-12-2

(RS)-isoserine

ammonium hydroxide

ammonium hydroxide

glycidic acid
503-11-7

glycidic acid

(RS)-isoserine
632-12-2

(RS)-isoserine

Conditions
ConditionsYield
at 120℃; im Einschlussrohr;
hydrogenchloride
7647-01-0

hydrogenchloride

glycidic acid
503-11-7

glycidic acid

3-chloro-2-hydroxypropanoic acid
1713-85-5

3-chloro-2-hydroxypropanoic acid

503-11-7Relevant articles and documents

Characterization of the enantioselective properties of the quinohemoprotein alcohol dehydrogenase of Acetobacter pasteurianus LMG 1635. 1. Different enantiomeric ratios of whole cells and purified enzyme in the kinetic resolution of racemic glycidol

Machado, Sonia Salgueiro,Wandel, Ute,Jongejan, Jaap A.,Straathof, Adrie J. J.,Duine, Johannis A.

, p. 10 - 20 (1999)

Resting cells of Acetobacter pasteurianus LMG 1635 (ATCC 12874) show appreciable enantioselectivity (E=16-18) in the oxidative kinetic resolution of racemic 2,3-epoxy-1-propanol, glycidol. Distinctly lower values (E=7-9) are observed for the ferricyanide-coupled oxidation of glycidol by the isolated quinohemoprotein alcohol dehydrogenase, QH-ADH, which is responsible for the enantiospecific oxidation step in whole cells. The accuracy of E-values from conversion experiments could be verified using complementary methods for the measurement of enantiomeric ratios. Effects of pH, detergent, the use of artificial electron acceptors, and the presence of intermediate aldehydes, could be accounted for. Measurements of E-values at successive stages of the purification showed that the drop in enantioselectivity correlates with the separation of QH-ADH from the cytoplasmic membrane. It is argued that the native arrangement of QH-ADH in the membrane-associated complex favors the higher E-values. The consequences of these findings for the use of whole cells versus purified enzymes in biocatalytic kinetic resolutions of chiral alcohols are discussed.

Efficient epoxidation of electron-deficient alkenes with hydrogen peroxide catalyzed by [γ-PW10O38V2(μ-OH) 2]3-

Kamata, Keigo,Sugahara, Kosei,Yonehara, Kazuhiro,Ishimoto, Ryo,Mizuno, Noritaka

scheme or table, p. 7549 - 7559 (2011/08/03)

A divanadium-substituted phosphotungstate, [γ-PW10O 38V2(μ-OH)2]3- (I), showed the highest catalytic activity for the H2O2-based epoxidation of allyl acetate among vanadium and tungsten complexes with a turnover number of 210. In the presence of I, various kinds of electron-deficient alkenes with acetate, ether, carbonyl, and chloro groups at the allylic positions could chemoselectively be oxidized to the corresponding epoxides in high yields with only an equimolar amount of H2O2 with respect to the substrates. Even acrylonitrile and methacrylonitrile could be epoxidized without formation of the corresponding amides. In addition, I could rapidly (min) catalyze epoxidation of various kinds of terminal, internal, and cyclic alkenes with H;bsubesubbsubesub& under the stoichiometric conditions. The mechanistic, spectroscopic, and kinetic studies showed that the I-catalyzed epoxidation consists of the following three steps: 1) The reaction of I with H;bsubesubbsubesub& leads to reversible formation of a hydroperoxo species [I;circbsubesubbsubesubbsubesubcirccircbsupesup& (II), 2) the successive dehydration of II forms an active oxygen species with a peroxo group [ 2:2-O2)]3- (III), and 3) III reacts with alkene to form the corresponding epoxide. The kinetic studies showed that the present epoxidation proceeds via III. Catalytic activities of divanadium-substituted polyoxotungstates for epoxidation with H 2O2 were dependent on the different kinds of the heteroatoms (i.e., Si or P) in the catalyst and I was more active than [γ-SiW10O38V2(μ-OH)2] 4-. On the basis of the kinetic, spectroscopic, and computational results, including those of [γ-SiW10O38V 2(μ-OH)2]4-, the acidity of the hydroperoxo species in II would play an important role in the dehydration reactivity (i.e., k3). The largest k3 value of I leads to a significant increase in the catalytic activity of I under the more concentrated conditions. Copyright

Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-Parkinson prodrugs

More, Swati S.,Vince, Robert

supporting information; experimental part, p. 4581 - 4588 (2009/06/06)

Plethoras of CNS-active drugs fail to effect their pharmacologic response due to their in vivo inability to cross the blood-brain barrier (BBB). The classical prodrug approach to overcome this frailty involves lipophilic derivatives of the polar drug, but we herein report a novel approach by which endogenous transporters at BBB are exploited for brain drug delivery. The crucial role played by glutathione in pathogenesis of Parkinson's and the presence of its influx transporters at the basolateral membrane of BBB served as the basis for our anti-Parkinson prodrug design strategy. A metabolically stable analogue of glutathione is used as a carrier for delivery of dopamine and adamantamine. An account of successful syntheses of these prodrugs along with their transport characteristics and stability determination is discussed.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 503-11-7